Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

IGC Pharma (IGC) Other financing activities (2017 - 2018)

IGC Pharma has reported Other financing activities over the past 3 years, most recently at $79747.0 for Q1 2018.

Quarterly Other financing activities changed N/A to $79747.0 in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $114393.0 through Mar 2018, up 437.28% year-over-year, with the annual reading at $191000.0 for FY2018, N/A changed from the prior year.
Other financing activities was $79747.0 for Q1 2018 at IGC Pharma, up from $34646.0 in the prior quarter.
Over five years, Other financing activities peaked at $79747.0 in Q1 2018 and troughed at $34646.0 in Q2 2017.